Wegovy and Possible Vision Risk - Top-Institutions - MDSpire

Wegovy and Possible Vision Risk

Higher dose weight loss injectable demonstrates nearly five times higher ischaemic optic neuropathy risk than other semaglutide GLP-1 agonists

  • April 8, 2026

  • 3 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Ophthalmology
    • Endocrinology
    • Neuro-ophthalmology

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Ophthalmology
    • Endocrinology
    • Clinical Pharmacology

  • #3

    Massachusetts General Hospital / Harvard Medical School
    Massachusetts General Hospital / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Ophthalmology
    • Endocrinology
    • Clinical Research

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Ophthalmology
    • Endocrinology
    • Neuro-ophthalmology

  • #5

    University of Toronto
    University of Toronto

    Toronto, ON

    Key Differentiators

    • Ophthalmology
    • Endocrinology
    • Pharmacovigilance

Original Source(s)

Wegovy and Possible Vision Risk

  • April 8, 2026

Related Content

Semaglutide Linked to NAION Risk

A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.

Diabetic Retinal Disease Rates Narrow by Diabetes Type

US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.

AI Boosts Diabetic Eye Care Access

Recent study highlights how integrated AI-assisted DR screening in primary care clinics can improve access and decrease disparity

  • May 5, 2026

  • 3 min